The paper examines through modeling the number of events avoided with anticoagulation therapy with new drugs versus VKAs for patients with atrial fibrillation, in the French context.
CHEVALIER, J., GIROUD, M. and PUYOU DE POUVOURVILLE, G. (2013). Modeling of the Impact on Health Outcomes of the Use of Dabigatran in Patients with Atrial Fibrillation. Cerebrovascular Diseases, 35(4), pp. 320-326.